Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18702115 | 0.81 | NAMPT (0.44) | NAMPTCDK1MYT1 | |
| SCHEMBL25937813 | 0.80 | SIGMAR1 (0.47) | NR1H2NAMPTALDH1A1CDK1MYT1 | |
| SCHEMBL18711411 | 0.79 | NAMPT (0.47) | ATMNAMPTCDK1MYT1 | |
| SCHEMBL29192669 | 0.77 | NAMPT (0.48) | POLBNAMPTCDK1MYT1 | |
| SCHEMBL2752666 | 0.75 | NR1H2 (0.53) | NR1H2POLBGPR119NAMPTESR2 | |
| SCHEMBL29215763 | 0.75 | NAMPT (0.47) | POLBHTTNAMPTALDH1A1CDK1 | |
| SCHEMBL30878026 | 0.75 | NAMPT (0.50) | POLBNAMPTCDK1MYT1 | |
| SCHEMBL25629845 | 0.75 | NAMPT (0.44) | NAMPTCDK1MYT1 | |
| SCHEMBL12307403 | 0.74 | NR1H2 (0.52) | NR1H2POLBGPR119ESR2MAPT | |
| SCHEMBL17926309 | 0.74 | NR1H2 (0.49) | NR1H2POLBGPR119HTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025051129-A1 | ARYL HETEROCYCLIC SLC7A11 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119552124-A | Aryl heterocycle SLC7A11 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240343742-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2024-10-17 | — | — | US | disclosed |
| US-11999752-B2 | Vinyl imidazole compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4349828-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117586265-A | Nitrogen-containing heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230391785-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME AND USE OF SAME | 280 BIO, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2022247770-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海璎黎药业有限公司 | 2022-12-01 | — | — | WO | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3245206-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. Hoffmann-La Roche AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1286967-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087838-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | NR1H2 284/4885POLB 2365/4885GPR119 923/4885 |
| US-20230391785-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME AND USE OF SAME | NRAS, KRAS, REN | NR1H2 1968/4885POLB 3821/4885GPR119 2104/4885 |
| US-20240343742-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | NR1H2 2650/4885POLB 813/4885GPR119 2296/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | NR1H2 42/4885POLB 1770/4885GPR119 269/4885 |
| US-11999752-B2 | Vinyl imidazole compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | NR1H2 2650/4885POLB 813/4885GPR119 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.